When will the annual report be_老虎社区_美港股上老虎

When will the annual report be released?

I-Mab to Participate in Leerink Partners Global Healthcare Conference<blockquote>天境生物将参加Leerink Partners全球医疗保健会议</blockquote>

ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents

I-Mab to Participate in Leerink Partners Global Healthcare Conference<blockquote>天境生物将参加Leerink Partners全球医疗保健会议</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":407852692410848,"tweetId":"407852692410848","gmtCreate":1740588457205,"gmtModify":1740588458326,"author":{"id":4151507249215430,"idStr":"4151507249215430","authorId":4151507249215430,"authorIdStr":"4151507249215430","name":"lucky 吼吼","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>When will the annual report be released?</body></html>","htmlText":"<html><head></head><body>When will the annual report be released?</body></html>","text":"When will the annual report be released?","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/407852692410848","repostId":2512159824,"repostType":2,"repost":{"id":"2512159824","kind":"highlight","weMediaInfo":{"introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"media_name":"GlobeNewswire","id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"pubTimestamp":1739880000,"share":"https://www.laohu8.com/m/news/2512159824?lang=zh_CN&edition=full","pubTime":"2025-02-18 20:00","market":"hk","language":"en","title":"I-Mab to Participate in Leerink Partners Global Healthcare Conference<blockquote>天境生物将参加Leerink Partners全球医疗保健会议</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2512159824","media":"GlobeNewswire","summary":"ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents","content":"<html><body>ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of cancer, today announced that members of I-Mab’s management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday and Wednesday, March 11-12, 2025.<blockquote><html><body>马里兰州洛克维尔，2025年2月18日（环球通讯社）——天境生物（纳斯达克：IMAB）（以下简称“公司”）是一家总部位于美国的全球生物技术公司，专注于精准免疫肿瘤药物的开发用于治疗癌症的药物，今天宣布天境生物管理层成员将参加2025年3月11日至12日（星期二）和（星期三）在佛罗里达州迈阿密举行的Leerink Partners全球医疗保健会议上举行的一对一会议。</body></html></blockquote> About I-Mab<blockquote>关于天境生物</blockquote> I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.<blockquote>天境生物（纳斯达克：IMAB）是一家总部位于美国的全球生物技术公司，专门专注于开发用于治疗癌症的精准免疫肿瘤药物。天境生物已在马里兰州洛克维尔和新泽西州肖特山建立了业务。欲了解更多信息，请访问https://www.i-mabbiopharma.com并在LinkedIn和X上关注我们。</blockquote> I-Mab Investor &amp; Media Contacts PJ Kelleher LifeSci Advisors +1-617-430-7579 pkelleher@lifesciadvisors.com IR@imabbio.com<blockquote>天境生物投资者和媒体联系人 PJ凯莱赫 LifeSci顾问 +1-617-430-7579 pkelleher@lifesciadvisors.com IR@imabbio.com</blockquote> <img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MThkYmJjYWUtNTliMC00OGRkLThmYzQtOWJiNGM1MDZjNjc0LTUwMDEyNTAyOQ==/tiny/I-Mab-Biopharma.png\"/></body></html><blockquote> </blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>I-Mab to Participate in Leerink Partners Global Healthcare Conference<blockquote>天境生物将参加Leerink Partners全球医疗保健会议</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nI-Mab to Participate in Leerink Partners Global Healthcare Conference<blockquote>天境生物将参加Leerink Partners全球医疗保健会议</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nGlobeNewswire \n2025-02-18 20:00\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body>ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of cancer, today announced that members of I-Mab’s management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday and Wednesday, March 11-12, 2025.<blockquote><html><body>马里兰州洛克维尔，2025年2月18日（环球通讯社）——天境生物（纳斯达克：IMAB）（以下简称“公司”）是一家总部位于美国的全球生物技术公司，专注于精准免疫肿瘤药物的开发用于治疗癌症的药物，今天宣布天境生物管理层成员将参加2025年3月11日至12日（星期二）和（星期三）在佛罗里达州迈阿密举行的Leerink Partners全球医疗保健会议上举行的一对一会议。</body></html></blockquote> About I-Mab<blockquote>关于天境生物</blockquote> I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.<blockquote>天境生物（纳斯达克：IMAB）是一家总部位于美国的全球生物技术公司，专门专注于开发用于治疗癌症的精准免疫肿瘤药物。天境生物已在马里兰州洛克维尔和新泽西州肖特山建立了业务。欲了解更多信息，请访问https://www.i-mabbiopharma.com并在LinkedIn和X上关注我们。</blockquote> I-Mab Investor &amp; Media Contacts PJ Kelleher LifeSci Advisors +1-617-430-7579 pkelleher@lifesciadvisors.com IR@imabbio.com<blockquote>天境生物投资者和媒体联系人 PJ凯莱赫 LifeSci顾问 +1-617-430-7579 pkelleher@lifesciadvisors.com IR@imabbio.com</blockquote> <img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MThkYmJjYWUtNTliMC00OGRkLThmYzQtOWJiNGM1MDZjNjc0LTUwMDEyNTAyOQ==/tiny/I-Mab-Biopharma.png\"/></body></html><blockquote> </blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓",".IXIC":"NASDAQ Composite","HCSG":"Healthcare Svcs Group Inc","BK4535":"淡马锡持仓","BK4139":"生物科技","TQQQ":"纳指三倍做多ETF","QID":"两倍做空纳斯达克指数ETF-ProShares","TSYW.SI":"TESLA 3xLongSG261006","USAW.SI":"AMZN 3xLongSG261006","NVIW.SI":"NVDA 3xLongSG261006","QLD":"2倍做多纳斯达克100指数ETF-ProShares","BK4137":"综合支持服务","SQQQ":"纳指三倍做空ETF","PSQ":"做空纳斯达克100指数ETF-ProShares","USJW.SI":"ALPHAB 3xLongSG261006","BK4526":"热门中概股"},"source_url":"https://www.globenewswire.com/news-release/2025/02/18/3027639/0/en/I-Mab-to-Participate-in-Leerink-Partners-Global-Healthcare-Conference.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2512159824","content_text":"ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of cancer, today announced that members of I-Mab’s management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday and Wednesday, March 11-12, 2025. About I-Mab I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X. I-Mab Investor & Media ContactsPJ KelleherLifeSci Advisors+1-617-430-7579pkelleher@lifesciadvisors.comIR@imabbio.com","news_type":1,"symbols_score_info":{"USAW.SI":0.6,"IMAB":1,"TQQQ":0.6,"HCSG":1,"MNQmain":0.6,"QID":0.6,"NVIW.SI":0.6,"TSYW.SI":0.6,".IXIC":0.73,"QLD":0.6,"SQQQ":0.6,"USJW.SI":0.6,"PSQ":0.6,"NQmain":0.6}},"isVote":1,"tweetType":1,"viewCount":1128,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":34,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}